Pricing Debate
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Coronavirus Vaccines As A Public Good: How Reasonable Is Reasonable?
During a recent press briefing, health officials in China disclosed the country is poised to reach an annual production capacity of 610 million doses for coronavirus vaccines. But they said prices must be based on manufacturing costs and not driven by supply and demand.
Latest From Pricing Debate
Lilly Signs US Bamlanivimab Contract, Raising Unanswered Allocation Considerations
The price of the antibody monotherapy for COVID-19 will be $1,250 per vial for wealthy countries. CEO David Ricks outlined the company's guidelines for pricing and distributing a limited supply.
Access And Affordability Are Key, Says New EMA Head
Ensuring patients have access to approved medicines is a key priority for Emer Cooke, the soon-to-be new head of the European Medicines Agency. Cooke says she will probably be a very different type of “captain” of the “wonderful ship” that is the EMA.
The Future Of Purdue: Will The ‘Public Benefit Corporation’ Model Take Off?
Purdue’s opioid settlement is making headlines for the size of the financial penalty. But the plan to re-imagine Purdue as a ‘public benefit company’ could have far-reaching significance for the industry – if it ever gets off the ground.
Biden, Germany And Bringing A National Drug Pricing Negotiation Process To US
Germany uses government facilitated price negotiations between publicly funded insurers and manufacturers that are based on an independent assessment of how much added value a drug provides.
German Insurers Want End To Free Pricing In Amnog Review
Insurers argue that better use of real world data and multiple pricing assessments could help lower drug prices in Germany.
COVID-19 And The Drug Pricing Debate: Disruption Helps Industry More Than R&D
CEO accountability hearing in US House shows that the COVID-19 outbreak is helping to blunt attacks on the drug industry over its pricing – just not entirely in the way the industry hoped.
Cost Offsets Crucial For Uptake Of Advanced Therapies
To maintain high prices and avoid access restrictions, companies marketing advanced therapies will have to show payers that their products save money elsewhere in the healthcare system.
French To Speed Up Early Access Procedure
The French government is to implement a simplified mechanism for making new, innovative medicines available to patients more quickly before they are formally approved for marketing. The target for reimbursement spending on health care in general has been increased for 2021 and includes a special provision for coronavirus-related expenditure.
Pharma Catches A Break As Democrats Stumble In Rollout Of Pricing Investigation
House Oversight Committee plans to grill more companies on pricing later this year, but rushed rollout of reports from a long-running investigation, combined with competing higher profile news events, seemed to dampen the blow of the latest drug pricing scrutiny. Democrats failed to offer any new, unified solutions for their grievances with industry, while Republicans largely rushed to pharma’s defense.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.